^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

B7-H3-targeted antibody-drug conjugate

Phase 1/2
Harpoon Therapeutics, Inc., a subsidiary of Mer...
Recruiting
Last update posted :
02/20/2025
Initiation :
12/14/2020
Primary completion :
06/30/2027
Completion :
06/30/2027
DLL3
|
DLL3 expression
|
Tecentriq (atezolizumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)
Phase 1
AbbVie
Active, not recruiting
Last update posted :
05/03/2024
Initiation :
07/13/2018
Primary completion :
12/31/2024
Completion :
12/31/2024
EGFR • HER-2 • BRAF • ALK • ROS1
|
PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • BRAF mutation • HER-2 negative • ALK mutation • ROS1 positive • HR positive + HER-2 negative • PTEN mutation + HR positive
|
paclitaxel • docetaxel • mirzotamab clezutoclax (ABBV-155)
Phase 1/2
DualityBio Inc.
Recruiting
Last update posted :
09/12/2023
Initiation :
09/05/2023
Primary completion :
04/01/2025
Completion :
04/01/2025
EGFR • KRAS • BRAF • ALK • MET • ROS1 • NTRK1 • NTRK3 • NTRK2 • CD276
|
BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • MET mutation • RET rearrangement • KRAS G12 • NTRK1 mutation • NTRK3 mutation
|
BNT324
Phase 1/2
Minghui Pharmaceutical Pty Ltd
Not yet recruiting
Last update posted :
01/09/2023
Initiation :
01/23/2023
Primary completion :
01/31/2026
Completion :
07/31/2026
MSI
|
MSI-H/dMMR
|
MHB088C